COSTEM 2019 | Should upfront CAR-T be part of the early MM treatment?

Philip McCarthy

Philip McCarthy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses whether upfront CAR-T cell therapy should be part of the early MM treatment. BCMA, MRD and antibody-drug conjugates are also discussed. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics